Status:
COMPLETED
Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
Lead Sponsor:
Sanofi
Conditions:
Noonan Syndrome
Eligibility:
All Genders
3-15 years
Phase:
PHASE3
Brief Summary
1. Clinical Objective : To improve the growth of these children 2. Genetic objective : A study of the genetics of the syndrome
Eligibility Criteria
Inclusion
- Children and adolescents with Noonan's syndrome with a height \< -2 SD and no progressive cardiopathy
Exclusion
- Age \< 3 years
- Height ≥ -2 SD
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
October 1 1997
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00452725
Start Date
October 1 1997
End Date
July 1 2010
Last Update
October 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Paris, France